| Company Name: |
Jinan Trio PharmaTech Co., Ltd.
|
| Tel: |
0531-88811783 |
| Email: |
sales@trio-pharmatech.com |
| Products Intro: |
Product Name:BM-1074
CAS:1391108-10-3
Purity:99% Package:5Mg, 10Mg, 20Mg, 50Mg
|
| Company Name: |
AdooQ BioScience, LLC
|
| Tel: |
+1 (866) 930-6790 |
| Email: |
info@adooq.com |
| Products Intro: |
Product Name:BM-1074
CAS:1391108-10-3
Purity:98% Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Products Intro: |
Product Name:BM-1074
CAS:1391108-10-3
Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:BM-1074
CAS:1391108-10-3
Purity:NULL Package:100mg;10mg;5mg Remarks:NULL
|
|
| | BM-1074 Basic information |
| Product Name: | BM-1074 | | Synonyms: | BM-1074;1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-4-[3-[4-[4-[[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]amino]phenyl]-1-piperazinyl]phenyl]-2-methyl-1-(1-methylethyl)-N-(methylsulfonyl)- | | CAS: | 1391108-10-3 | | MF: | C50H57ClN8O7S3 | | MW: | 1013.68 | | EINECS: | | | Product Categories: | | | Mol File: | 1391108-10-3.mol |  |
| | BM-1074 Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO mg/mL Water mg/mL Ethanol mg/mL | | pka | 2.32±0.40(Predicted) |
| | BM-1074 Usage And Synthesis |
| Uses | BM-1074 is a potent Bcl-2/Bcl-xL inhibitor which is capable of achieving rapid, complete, and durable tumor regression in vivo. | | in vivo | BM-1074 (i.v., 15 mg/kg, daily, 5 days a week for 2 weeks) exhibits the maximum tolerated dose (MTD) (15 mg/kg) and strong antitumor activity in H146 tumor xenograft mice, as well as shows no significant weight loss (<5%) or other signs of toxicity[1].
BM-1074 (i.v., 15 mg/kg, single) induces strong apoptosis in H146 tumor tissues[1].
| Animal Model: | SCID mice (injected with 5 x 106 H146 cancer cells with Matrigel, subcutaneously)[1] | | Dosage: | 15 mg/kg | | Administration: | i.v., 15 mg/kg, daily, 5 days a week for 2 weeks | | Result: | Showed good toleration and did not cause significant weight loss or other signs of toxicity, also induced completely and persistent tumor regression in the H146 xenograft model. |
| Animal Model: | SCID mice (injected with 5 x 106 H146 cancer cells with Matrigel, subcutaneously)[1] | | Dosage: | 15 mg/kg | | Administration: | i.v., 15 mg/kg, single dosage | | Result: | Induced robust cleavage of PARP and caspase-3 at both 3 and 6-hr time-points in H146 tumor tissues. |
| | IC 50 | Bcl-2: 1.8 nM (IC50); Bcl-xL: 6.9 nM (IC50) |
| | BM-1074 Preparation Products And Raw materials |
|